Sutro Biopharma (NASDAQ: STRO - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Rep

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperfor

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and

Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces chall

Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dos

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess

Dow Jones up 0.1%, NASDAQ up 0.47%, S&P 500 up 0.24%. Tech stocks up 1.1%, communication service

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.33) per share which missed the analys

– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses

Wall Street analysts reshuffled their ratings on Friday with some bold calls that could move money f

Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 4

Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rati

Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overwei

U.S. stock futures lower with Nasdaq down 200 points. XP Inc (XP) falls after reporting lower-than-e

Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial

Leerink Partners maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and raises the price ta

Wedbush analyst David Nierengarten upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Outperf

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after stro

Analysts change outlook on top Wall Street names. Piper Sandler cuts target for Figma to $30, Roth C

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STR

Top analysts change outlook on top names, including upgrades, downgrades, and initiations. Check out

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading se

Mizuho analyst Salim Syed initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Outperform r

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperfor

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid t

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid t

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report)'s stock price traded up 10.4% on Friday after

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperfor

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See ful

Top Wall Street analysts upgraded STRO, JKS, AJG, ECL, RL stocks. See analysts' ratings and pric

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC;

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given an average recommendation of "

Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-mont

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given a consensus recommendation of

Shares of Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) have received a consensus recommend

  During the session on Thursday, 461 stocks hit new 52-week lows.

  During Tuesday's session, 275 companies made new 52-week lows.